H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $35 from $33 and keeps a Buy rating on the shares after the company announced that Khindivi received FDA approval as replacement therapy in pediatric patients five years of age and older with adrenal insufficiency. The firm believes 2025 could be a year of revenue inflection for Eton.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals: Buy Rating Affirmed on Khindivi’s FDA Approval and Strong Revenue Growth Prospects
- Eton Pharmaceuticals Gains FDA Approval for KHINDIVI
- Eton Pharmaceuticals announces FDA approval for KHINDIVI
- Eton Pharmaceuticals price target raised to $26 from $24 at B. Riley
- Eton Pharmaceuticals’ Earnings Call: Growth and Prospects